SourceBio International PLC Medical supply support for the people of Ukraine

TIDMSBI

SourceBio International PLC

09 March 2022

SourceBio International plc

("SourceBio", the "Company" or the "Group")

Medical supply support for the people of Ukraine

SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services and products , announces that following the recent events in Ukraine, the Board wishes to extend some practical support to Ukraine.

The Group is assembling an express shipment of laboratory and medical consumables, laboratory equipment and ancillary supplies to be sent to assist, as urgently as possible, the people of Ukraine. Separately, the Group is committing GBP100,000 of cash funding to secure the delivery of trauma kits to Ukraine.

Christopher Mills, Director and Shareholder (Harwood Capital Management Group), commented: " The rest of the world has watched with horror the unfolding events in Ukraine following Russia's invasion. Russia has created an appalling situation that cannot be ignored and we all must stand up and support the people of Ukraine. It is the morally right thing to do. Myself and the rest of the SourceBio Board feel very deeply that we must offer some direct support. I would encourage all companies, public or private, whatever their size, to provide similar tangible support to Ukraine ."

Contacts:

 
 SourceBio International plc                                 www.sourcebiointernational.com 
 Jay LeCoque, Executive Chairman                                            Via Walbrook PR 
 Tony Ratcliffe, Chief Financial Officer 
 
 Walbrook PR Limited                         Tel: [phone] or [e-mail] 
 Paul McManus / Sam Allen                                        Mob: [phone] / 07502 
                                                                                    558 258 
 
 

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four business units:

-- Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.

-- Genomics - DNA sequencing services and Precision Medicine offering for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.

-- Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA

-- Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups and the NHS. Utilising multiple technologies, SourceBio offers screening, gold standard RT-PCR and whole genome sequencing COVID-19 testing solutions and operates under ISO 15189 accreditation. SourceBio also provides employee testing solutions to industry, direct to consumer home test kits and venue testing.

More details on Group operations can be found here: www.sourcebioscience.com

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABSGDXLBGDGDC

(END) Dow Jones Newswires

March 09, 2022 09:30 ET (14:30 GMT)